Matthew W. Kalnik is SVP Strategic Plan. & Bus. Ops at NABI BIOPHARMACEUTICALS (NABI). They have made 2 open-market trades across 1 company since 2009, most recently 2011-04-01.
CIK 0001459477
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NABI | 71,050 | — |
Shares reported on the most recent Form 4, priced at the 2011-04-05 close. 1 holding could not be priced and is excluded from the total.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NABI | SELL · 10b5-1 | 2011-04-01 | 2011-04-05 | $5.80 | $37K | N/A | N/A | N/A |
| NABI | SELL · 10b5-1 | 2010-07-26 | 2010-07-27 | $5.78 | $9K | N/A | N/A | N/A |
| NABI | SELL · 10b5-1 | 2010-07-19 | 2010-07-21 | $5.48 | $9K | N/A | N/A | N/A |
| NABI | SELL · 10b5-1 | 2010-04-13 | 2010-04-15 | $5.78 | $13K | N/A | N/A | N/A |
| NABI | SELL · 10b5-1 | 2010-04-01 | 2010-04-05 | $5.49 | $11K | N/A | N/A | N/A |
| NABI | SELL | 2010-03-17 | 2010-03-17 | $5.93 | $59K | N/A | N/A | N/A |
| NABI | SELL · 10b5-1 | 2010-03-11 | 2010-03-17 | $5.95 | $7K | N/A | N/A | N/A |
| NABI | SELL · 10b5-1 | 2010-03-02 | 2010-03-04 | $5.45 | $12K | N/A | N/A | N/A |
| NABI | SELL | 2009-11-16 | 2009-11-18 | $4.71 | $69K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.